Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508
Go back to Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 523.47 +12.75 (2.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $510.72 | 52 Week High | $134.71 | |||
| Open | $521.69 | 52 Week Low | $73.31 | |||
| Day High | $525.97 | P/E | N/A | |||
| Day Low | $508.14 | EPS | $-1.98 | |||
| Volume | 393,510 | |||||
